Oscar Health Board Member Plouffe David Buys 641 DSUs in Bold Pre‑Earnings Move — Insider Confidence on the Rise

Insider Activity at Oscar Health: What Plouffe David’s Latest Purchase Signals

Oscar Health’s board is in the middle of a flurry of insider transactions, and the newest move from Plouffe David—a non‑executive board member—adds a fresh layer of insight. On October 8, 2026, David bought 641 deferred stock units (DSUs) at the closing price of $33.10, bringing his post‑transaction holdings to 8,176 DSUs. The deal is part of the company’s deferred compensation plan, which awards units that vest immediately and are settled in cash or Class A shares within 45 days of certain events. Because the units vest instantly, the purchase reflects a commitment to stay on the board and to share in future upside.

Investor Takeaway: Confidence vs. Timing

For investors, the timing of the purchase is key. The transaction occurs just weeks before Oscar Health is set to release its third‑quarter 2026 earnings on November 5. The DSU structure means David can convert these units into shares later—potentially providing a liquidity event that aligns his interests with shareholders. The market’s reaction has been neutral, with a slight price dip of 0.01% and a modest positive sentiment score of +30 on social media. However, the buzz factor—451 %—indicates heightened chatter, perhaps driven by the anticipation of the upcoming earnings report. If the company reports strong growth or new product launches, the value of those DSUs could rise sharply, offering David—and any other holders—a profitable exit window.

What Plouffe David Has Done So Far

Looking at David’s historical activity, the pattern is one of consistent accumulation. Between January and October 2026, he purchased 681 DSUs at $31.20, 1,461 DSUs at $14.54, 1,257 DSUs at $16.90, 1,034 DSUs at $20.54, and an additional 641 DSUs in October. In the same period, he also bought 8,475 Class A shares at $0.00—likely a zero‑price transfer or an error in the filing. The steady buying trend suggests that David is bullish on Oscar’s long‑term trajectory, perhaps anticipating continued expansion of its technology platform and market share.

Broader Insider Landscape

Oscar Health’s board and senior executives are also active. On the same day, Sankaran Sid and William Gassen each bought 1,472 and 698 DSUs, respectively, reinforcing the sense that the top tier believes in the company’s prospects. In contrast, a sizable sell‑off by co‑founder Joshua Kushner earlier in September—over 6 million Class A shares—highlights a potential realignment among founding stakeholders, possibly to free capital for other ventures or to diversify holdings. The mix of purchases and sales across the board signals a dynamic, evolving governance structure that may affect shareholder sentiment.

What to Watch

1. Conversion of DSUs: Watch the company’s quarterly statements for any announcements on converting DSUs to shares, as this could trigger short‑term price moves.
2. Earnings Release: The November 5 earnings call will be pivotal. Strong results could validate the insider optimism and boost stock performance.
3. Executive Movements: Monitor any changes in the board composition or executive compensation plans, as they may influence future DSU issuance.

In sum, Plouffe David’s recent DSU purchase is a bullish sign amid a broader pattern of insider confidence. While the current market reaction is muted, the impending earnings report and the potential for DSU conversion could create short‑term volatility. For investors, this activity underscores the importance of staying attuned to insider transactions and the company’s strategic disclosures.